Stockreport

BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights

BioXcel Therapeutics, Inc.  (BTAI) 
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am Check Earnings Report
PDF Received FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults [Read more]